Edgewise Therapeutics(US:EWTX)2025-11-06 13:00Financial Performance - As of September 30, 2025, cash, cash equivalents, and marketable securities totaled approximately $563.3 million, up from $470.2 million at the end of 2024, reflecting a significant increase in liquidity[14][22]. - The net loss for Q3 2025 was $40.7 million, or $0.39 per share, compared to a net loss of $36.1 million, or $0.34 per share, in the previous quarter[16][21]. Research and Development - Research and development (R&D) expenses for Q3 2025 were $37.5 million, an increase of 11.5% from $33.6 million in the previous quarter, driven by clinical development activities for EDG-15400 and EDG-7500[15][21]. - The CIRRUS-HCM Phase 2 trial of EDG-7500 is ongoing, with a program update anticipated in Q4 2025 and comprehensive data expected in the first half of 2026[10]. - EDG-15400 is currently in a Phase 1 trial for heart failure, with topline results expected in the first half of 2026[11]. - The company is actively developing Phase 3 trial designs for HCM and Duchenne muscular dystrophy, with plans to meet with the FDA regarding these studies[8][18]. Clinical Trials - Enrollment in the MESA open-label extension trial for sevasemten in Becker muscular dystrophy reached 99% of eligible participants as of September 2025[4]. - The GRAND CANYON pivotal trial for sevasemten in Becker muscular dystrophy completed enrollment in February 2025, with 175 adults enrolled across 12 countries, and topline data expected in Q4 2026[5]. Community Engagement - Edgewise Therapeutics continues to engage with the scientific and patient communities through various congresses and educational events, enhancing its outreach efforts[13].